Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

Trial ID or NCT#

NCT01683084

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to determine if telmisartan is effective in slowing the progression of abdominal aortic aneurysms and reducing circulating concentrations of Abdominal Aortic Aneurysms (AAA) biomarkers.

Official Title

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

Eligibility Criteria

Ages Eligible for Study: 50 Years to 85 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - 50-85 years of age and able to provide written informed consent - AAA measuring a maximum diameter of 3.5-4.9 cm on CTA or ultrasound - Stable medication regime for the last six months - No current indication for AAA repair according to the treating physician or expectation that this will be revised within the next year - High likelihood of compliance with treatment over 24 months
Exclusion Criteria:
  1. - Renal impairment (i.e. creatinine >1.5x upper limit of normal [ULN]) - Known significant renal stenosis (>70%) of one or both renal arteries - Chronic liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function (i.e. ALT 1.5xULN) - Electrolyte imbalance - Active gout - Current or planned usage of an AT1 blocker or ACE inhibitor - Previous abdominal aortic surgery - Currently pregnant or intend to become pregnant

Investigator(s)

Ronald L. Dalman MD
Ronald L. Dalman MD
Vascular surgeon
Dr. Walter C. Chidester Professor
Oliver O. Aalami, MD
Vascular surgeon
Clinical Professor, Surgery - Vascular Surgery

Contact us to find out if this trial is right for you.

Contact

Ronald Dalman
6507232169